Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Receivables (2017 - 2019)

Arcus Biosciences has reported Receivables over the past 3 years, most recently at $62000.0 for Q2 2019.

  • Quarterly results put Receivables at $62000.0 for Q2 2019, down 84.22% from a year ago — trailing twelve months through Jun 2019 was $62000.0 (down 84.22% YoY), and the annual figure for FY2018 was $183000.0, up 266.0%.
  • Receivables for Q2 2019 was $62000.0 at Arcus Biosciences, down from $183000.0 in the prior quarter.
  • Over the last five years, Receivables for RCUS hit a ceiling of $5.1 million in Q3 2018 and a floor of $50000.0 in Q4 2017.
  • Median Receivables over the past 3 years was $145500.0 (2018), compared with a mean of $982666.7.
  • Biggest five-year swings in Receivables: skyrocketed 266.0% in 2018 and later crashed 84.22% in 2019.
  • Arcus Biosciences' Receivables stood at $50000.0 in 2017, then skyrocketed by 266.0% to $183000.0 in 2018, then plummeted by 66.12% to $62000.0 in 2019.
  • The last three reported values for Receivables were $62000.0 (Q2 2019), $183000.0 (Q4 2018), and $5.1 million (Q3 2018) per Business Quant data.